Industry News
Biotechnology Industry News
Astellas is preparing to close its…
Astellas is preparing to close its Seattle site for its stem cell therapy unit, with around 55 employees set to be affected.
Takeda has pulled back from a…
Takeda has pulled back from a research collaboration with a fellow Japanese life sciences company, ending work to discover new small molecules that target mRNA.
Kazia Therapeutics is paying $1.4…
Kazia Therapeutics is paying $1.4 million upfront to secure a platform for generating epigenetic drugs from an Australian research institute.
Eli Lilly has turned its attention…
Eli Lilly has turned its attention down south with a $300 million biobuck acquisition of Houston-based CrossBridge Bio, aiming to advance its dual-payload antibody-drug conjugate (ADCs) pipeline.
An FDA review of records found…
An FDA review of records found that results have not been reported for 30% of registered clinical studies. To remedy this shortfall, the U.S. regulator has sent reminders to 2,200 drug companies, medical device manufacturers
Discover how biomarker strategies…
Discover how biomarker strategies are transforming oncology trials and accelerating precision medicine breakthroughs.
Kailera is taking another step…
Kailera is taking another step into the competitive obesity market by aiming to raise up to $528.5 million via a Nasdaq IPO, with proceeds intended to advance its GLP-1 assets through clinical development.
Spyre Therapeutics’ monoclonal…
Spyre Therapeutics’ monoclonal antibody hit the key goal in a phase 2 study for ulcerative colitis, which the company has touted as proof it can best Takeda’s Entyvio.
AbbVie has agreed to pay $30…
AbbVie has agreed to pay $30 million upfront to Chinese biotech Haisco Pharmaceutical Group for two non-opioid pain treatment candidates.
A phase 2/3 trial of Ideaya…
A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of the year.
Revolution Medicines’ pan-RAS…
Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.
The fight for two tumor types is…
The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca and SynOx Therapeutics planning to enter a market served by companies including Daiichi Sankyo on the back
With its latest obesity play…
With its latest obesity play appearing to pay off, Regeneron has turned its attention to radiopharmaceuticals.
Cema-cel eradicated minimal…
Cema-cel eradicated minimal residual disease in seven of 12 patients, compared to two of 12 participants in the observational control arm.
Seaport Therapeutics and Hemab…
Seaport Therapeutics and Hemab Therapeutics are both charting a course for the public markets.
Boehringer Ingelheim and Amgen…
Boehringer Ingelheim and Amgen have both canned early-stage immunology candidates after the prospects showed little clinical promise.
The second time is not the charm…
The second time is not the charm for Replimune’s melanoma candidate RP1. After spurning the immunotherapy last July, the FDA has now rejected the biotech’s resubmitted application.
Oricell Therapeutics has now…
Oricell Therapeutics has now raised over $110 million in its final funding round before the Chinese CAR-T therapy biotech seeks to go public.
When Fierce last caught up with…
When Fierce last caught up with GSK’s head of oncology R&D back in November, we were told to “stay tuned” for the pharma to publish its own hotly anticipated data on a pair of antibody-drug
The Orano group has selected a new…
The Orano group has selected a new leader for its oncology-focused Orano Med subsidiary in Frederic Desdouits, who has sat on the governance board of the company since 2022. Desdouits’ appointment was attributed to his